Discontinuation of anticoagulant treatment

From clinical trials to medication persistence

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: The new generation, non-vitamin K antagonist oral anticoagulants are used in an increasing frequency, partially replacing the vitamin K antagonists in several fields of anticoagulation. Efficacy of the preventive oral anticoagulant regime, however, may be compromised by patient non-compliance. Methods: The authors analyzed treatment discontinuation frequencies in phase 3 trials of anticoagulant treatment in non-valvular atrial fibrillation in a frequentist random effect metaanalysis and in Bayesian multiple treatment network comparison. Results: Frequency of discontinuations are heterogeneous and highly inconsistent (Chi2 test for heterogeneity p>0.001, I2 test for inconsistency 95.1%). Discontinuations were the most frequent with dabigatran followed by rivaroxaban, warfarin, edoxaban and apixaban. Rivaroxaban were less frequently discontinued when compared to the two doses of dabigatran. (OR 0.80; 95% CI: 0.71'0.91 versus 150 mg b.i.d., and OR: 0.77; 95% CI: 0.68'0.87 versus 110 mg b.i.d.). Conclusion: Important differences exist among the treatment adherence of different anticoagulant protocols. Discontinuation rates experienced during the clinical trials may predict the real life patient adherence.

Original languageEnglish
Pages (from-to)1841-1844
Number of pages4
JournalCurrent Medical Research and Opinion
Volume31
Issue number10
DOIs
Publication statusPublished - Oct 3 2015

Fingerprint

Medication Adherence
Anticoagulants
Clinical Trials
Patient Compliance
Vitamin K
Warfarin
Atrial Fibrillation
Dabigatran
Rivaroxaban

Keywords

  • Anticoagulant adherence
  • NOACS
  • Non-vitamin-Kantagonist oral anticoagulants
  • Vitamin K antagonists

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Discontinuation of anticoagulant treatment : From clinical trials to medication persistence. / Komócsi, A.

In: Current Medical Research and Opinion, Vol. 31, No. 10, 03.10.2015, p. 1841-1844.

Research output: Contribution to journalArticle

@article{84923bd29ef64260ae2425b175e9d13e,
title = "Discontinuation of anticoagulant treatment: From clinical trials to medication persistence",
abstract = "Background: The new generation, non-vitamin K antagonist oral anticoagulants are used in an increasing frequency, partially replacing the vitamin K antagonists in several fields of anticoagulation. Efficacy of the preventive oral anticoagulant regime, however, may be compromised by patient non-compliance. Methods: The authors analyzed treatment discontinuation frequencies in phase 3 trials of anticoagulant treatment in non-valvular atrial fibrillation in a frequentist random effect metaanalysis and in Bayesian multiple treatment network comparison. Results: Frequency of discontinuations are heterogeneous and highly inconsistent (Chi2 test for heterogeneity p>0.001, I2 test for inconsistency 95.1{\%}). Discontinuations were the most frequent with dabigatran followed by rivaroxaban, warfarin, edoxaban and apixaban. Rivaroxaban were less frequently discontinued when compared to the two doses of dabigatran. (OR 0.80; 95{\%} CI: 0.71'0.91 versus 150 mg b.i.d., and OR: 0.77; 95{\%} CI: 0.68'0.87 versus 110 mg b.i.d.). Conclusion: Important differences exist among the treatment adherence of different anticoagulant protocols. Discontinuation rates experienced during the clinical trials may predict the real life patient adherence.",
keywords = "Anticoagulant adherence, NOACS, Non-vitamin-Kantagonist oral anticoagulants, Vitamin K antagonists",
author = "A. Kom{\'o}csi",
year = "2015",
month = "10",
day = "3",
doi = "10.1185/03007995.2015.1086991",
language = "English",
volume = "31",
pages = "1841--1844",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Discontinuation of anticoagulant treatment

T2 - From clinical trials to medication persistence

AU - Komócsi, A.

PY - 2015/10/3

Y1 - 2015/10/3

N2 - Background: The new generation, non-vitamin K antagonist oral anticoagulants are used in an increasing frequency, partially replacing the vitamin K antagonists in several fields of anticoagulation. Efficacy of the preventive oral anticoagulant regime, however, may be compromised by patient non-compliance. Methods: The authors analyzed treatment discontinuation frequencies in phase 3 trials of anticoagulant treatment in non-valvular atrial fibrillation in a frequentist random effect metaanalysis and in Bayesian multiple treatment network comparison. Results: Frequency of discontinuations are heterogeneous and highly inconsistent (Chi2 test for heterogeneity p>0.001, I2 test for inconsistency 95.1%). Discontinuations were the most frequent with dabigatran followed by rivaroxaban, warfarin, edoxaban and apixaban. Rivaroxaban were less frequently discontinued when compared to the two doses of dabigatran. (OR 0.80; 95% CI: 0.71'0.91 versus 150 mg b.i.d., and OR: 0.77; 95% CI: 0.68'0.87 versus 110 mg b.i.d.). Conclusion: Important differences exist among the treatment adherence of different anticoagulant protocols. Discontinuation rates experienced during the clinical trials may predict the real life patient adherence.

AB - Background: The new generation, non-vitamin K antagonist oral anticoagulants are used in an increasing frequency, partially replacing the vitamin K antagonists in several fields of anticoagulation. Efficacy of the preventive oral anticoagulant regime, however, may be compromised by patient non-compliance. Methods: The authors analyzed treatment discontinuation frequencies in phase 3 trials of anticoagulant treatment in non-valvular atrial fibrillation in a frequentist random effect metaanalysis and in Bayesian multiple treatment network comparison. Results: Frequency of discontinuations are heterogeneous and highly inconsistent (Chi2 test for heterogeneity p>0.001, I2 test for inconsistency 95.1%). Discontinuations were the most frequent with dabigatran followed by rivaroxaban, warfarin, edoxaban and apixaban. Rivaroxaban were less frequently discontinued when compared to the two doses of dabigatran. (OR 0.80; 95% CI: 0.71'0.91 versus 150 mg b.i.d., and OR: 0.77; 95% CI: 0.68'0.87 versus 110 mg b.i.d.). Conclusion: Important differences exist among the treatment adherence of different anticoagulant protocols. Discontinuation rates experienced during the clinical trials may predict the real life patient adherence.

KW - Anticoagulant adherence

KW - NOACS

KW - Non-vitamin-Kantagonist oral anticoagulants

KW - Vitamin K antagonists

UR - http://www.scopus.com/inward/record.url?scp=84942295547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942295547&partnerID=8YFLogxK

U2 - 10.1185/03007995.2015.1086991

DO - 10.1185/03007995.2015.1086991

M3 - Article

VL - 31

SP - 1841

EP - 1844

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 10

ER -